Consolidated Statement Of Profit Or Loss

Takeda Pharmaceutical Company Limited - Filing #7251660

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Consolidated statement of profit or loss
Statement of profit or loss
Revenue
4,581,551,000,000 JPY
4,263,762,000,000 JPY
Cost of sales
1,580,217,000,000 JPY
1,426,678,000,000 JPY
Selling, general and administrative expenses
1,104,766,000,000 JPY
1,053,819,000,000 JPY
Other income
26,212,000,000 JPY
19,379,000,000 JPY
Other expenses
206,733,000,000 JPY
206,527,000,000 JPY
Operating profit (loss)
342,586,000,000 JPY
214,075,000,000 JPY
Finance income
46,549,000,000 JPY
52,093,000,000 JPY
Finance costs
210,065,000,000 JPY
219,850,000,000 JPY
Share of profit (loss) of investments accounted for using equity method
-3,986,000,000 JPY
6,473,000,000 JPY
Profit (loss) before tax
175,084,000,000 JPY
52,791,000,000 JPY
Income tax expense
66,941,000,000 JPY
-91,406,000,000 JPY
Profit (loss)
JPY
107,928,000,000 JPY
107,928,000,000 JPY
215,000,000 JPY
108,143,000,000 JPY
144,067,000,000 JPY
144,067,000,000 JPY
144,197,000,000 JPY
JPY
130,000,000 JPY
Profit (loss) attributable to
Owners of parent
107,928,000,000 JPY
144,067,000,000 JPY
Non-controlling interests
215,000,000 JPY
130,000,000 JPY
Earnings (loss) per share
Basic earnings (loss) per share
68.36
92.09
Diluted earnings (loss) per share
67.23
91.16

Talk to a Data Expert

Have a question? We'll get back to you promptly.